Patents by Inventor Toshiaki Takizawa

Toshiaki Takizawa has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20230321051
    Abstract: An FGF21 production promoting agent containing, as an active ingredient, a compound represented by the following formula (1): wherein each of R1 and R2, which may be identical to or different from each other, represents, for example, a hydrogen atom; each of R3a, R3b, R4a, and R4b, which may be identical to or different from one another, represents, for example, a hydrogen atom or a halogen atom, or R3a and R3b or R4a and R4b may bond together to form an alkylenedioxy group; X represents an oxygen atom, a sulfur atom, or N-R5 (R5 represents, for example, a hydrogen atom or a C1-4 alkyl group); Y represents, for example, an oxygen atom, an S(O)1 group (1 is a number of from 0 to 2), or a carbonyl group; Z represents CH or N; n is a number of from 1 to 6; and m is a number from 2 to 6, a salt of the compound, or a solvate of the compound or the salt.
    Type: Application
    Filed: May 24, 2023
    Publication date: October 12, 2023
    Applicant: Kowa Co., Ltd.
    Inventors: Toshiaki TAKIZAWA, Kentaro MURAKAMI
  • Publication number: 20230019803
    Abstract: An FGF21 production promoting agent containing, as an active ingredient, a compound represented by the following formula (1): wherein each of R1 and R2, which may be identical to or different from each other, represents, for example, a hydrogen atom; each of R3a, R3b, R4a, and R4b, which may be identical to or different from one another, represents, for example, a hydrogen atom or a halogen atom, or R3a and R3b or R4a and R4b may bond together to form an alkylenedioxy group; X represents an oxygen atom, a sulfur atom, or N—R5 (R5 represents, for example, a hydrogen atom or a C1-4 alkyl group); Y represents, for example, an oxygen atom, an S(O)l group (l is a number of from 0 to 2), or a carbonyl group; Z represents CH or N; n is a number of from 1 to 6; and m is a number from 2 to 6, a salt of the compound, or a solvate of the compound or the salt.
    Type: Application
    Filed: September 2, 2022
    Publication date: January 19, 2023
    Applicant: Kowa Co., Ltd.
    Inventors: Toshiaki TAKIZAWA, Kentaro MURAKAMI
  • Publication number: 20210205274
    Abstract: An FGF21 production promoting agent containing, as an active ingredient, a compound represented by the following formula (1): wherein each of R1 and R2, which may be identical to or different from each other, represents, for example, a hydrogen atom; each of R3a, R3b, R4a, and R4b, which may be identical to or different from one another, represents, for example, a hydrogen atom or a halogen atom, or R3a and R3b or R4a and R4b may bond together to form an alkylenedioxy group; X represents an oxygen atom, a sulfur atom, or N—R5 (R5 represents, for example, a hydrogen atom or a C1-4 alkyl group); Y represents, for example, an oxygen atom, an S(O)l group (l is a number of from 0 to 2), or a carbonyl group; Z represents CH or N; n is a number of from 1 to 6; and m is a number from 2 to 6, a salt of the compound, or a solvate of the compound or the salt.
    Type: Application
    Filed: February 26, 2021
    Publication date: July 8, 2021
    Applicant: Kowa Co., Ltd.
    Inventors: Toshiaki TAKIZAWA, Kentaro MURAKAMI
  • Patent number: 11013722
    Abstract: The present invention addresses the problem of providing a pharmaceutical combination composition and drug combinations for the prevention and/or treatment of dyslipidemic conditions such as atherosclerosis, hypercholesterolemia, low HDL blood disease in mammals including humans. A pharmaceutical composition for the prevention and/or treatment of dyslipidemia, etc. which comprises (a) a compound represented by the general formula (1) (in the formula, each symbol is the same as defined in the specification) or a salt thereof or a solvate thereof and (b) a cholesterol absorption inhibitor.
    Type: Grant
    Filed: February 11, 2019
    Date of Patent: May 25, 2021
    Assignee: KOWA COMPANY, LTD.
    Inventors: Toshiaki Takizawa, Yasunobu Yoshinaka
  • Patent number: 10993547
    Abstract: There is provided a cover-material fastening end member including a band-shaped member and a locking member. The locking member is formed such that a width thereof in a direction perpendicular to a surface of the band-shaped member is wider than a width of the band-shaped member. The locking member includes: a center plate-shaped portion, a flange portion, and a plurality of rib portions. The flange portion has a surface extending along a longitudinal direction of the end edge portion of the band-shaped member and perpendicular to a surface of the center plate-shaped portion. The rib portions each has a surface intersecting with the center plate-shaped portion and the flange portion. The rib portions are provided on the center plate-shaped portion along the longitudinal direction of the center plate-shaped portion at predetermined intervals.
    Type: Grant
    Filed: March 23, 2016
    Date of Patent: May 4, 2021
    Inventors: Wanli Zhang, Hikaru Okuyama, Ryuichi Murasaki, Toshiaki Takizawa, Kenji Dono
  • Publication number: 20200375371
    Abstract: There is provided a cover-material fastening end member including a band-shaped member and a locking member. The locking member is formed such that a width thereof in a direction perpendicular to a surface of the band-shaped member is wider than a width of the band-shaped member. The locking member includes: a center plate-shaped portion, a flange portion, and a plurality of rib portions. The flange portion has a surface extending along a longitudinal direction of the end edge portion of the band-shaped member and perpendicular to a surface of the center plate-shaped portion. The rib portions each has a surface intersecting with the center plate-shaped portion and the flange portion. The rib portions are provided on the center plate-shaped portion along the longitudinal direction of the center plate-shaped portion at predetermined intervals.
    Type: Application
    Filed: March 23, 2016
    Publication date: December 3, 2020
    Inventors: Wanli Zhang, Hikaru Okuyama, Ryuichi Murasaki, Toshiaki Takizawa, Kenji Dono
  • Publication number: 20200246314
    Abstract: This invention provides a combination-drug composition and a combination use of pharmaceuticals for preventing and/or treating dyslipidemic conditions such as hyper-LDL cholesterolemia in mammals, including humans. This invention pertains to a drug composition for preventing and/or treating dyslipidemia and the like, the drug composition including the following: (R)-2-[3-[[N-(benzoxazol-2-yl)-N-3-(4-methoxyphenoxy)propyl]aminomethyl]phenoxy] butyric acid, a salt thereof, or a solvate of either; and nicotinic acid and nicotinic-acid amide, collectively referred to as niacin, an ester derivative thereof, a salt thereof, or a solvate of any of these.
    Type: Application
    Filed: April 20, 2020
    Publication date: August 6, 2020
    Applicant: KOWA COMPANY, LTD.
    Inventors: Yuta Inokuchi, Toshiaki Takizawa
  • Publication number: 20200246315
    Abstract: An FGF21 production promoting agent containing, as an active ingredient, a compound represented by the following formula (1): wherein each of R1 and R2, which may be identical to or different from each other, represents, for example, a hydrogen atom; each of R3a, R3b, R4a, and R4b, which may be identical to or different from one another, represents, for example, a hydrogen atom or a halogen atom, or R3a and R3b or R4a and R4b may bond together to form an alkylenedioxy group; X represents an oxygen atom, a sulfur atom, or N—R5 (R5 represents, for example, a hydrogen atom or a C1-4 alkyl group); Y represents, for example, an oxygen atom, an S(O)l group (l is a number of from 0 to 2), or a carbonyl group; Z represents CH or N; n is a number of from 1 to 6; and m is a number from 2 to 6, a salt of the compound, or a solvate the compound or the salt.
    Type: Application
    Filed: April 22, 2020
    Publication date: August 6, 2020
    Applicant: Kowa Co., Ltd.
    Inventors: Toshiaki TAKIZAWA, Kentaro Murakami
  • Publication number: 20200030299
    Abstract: An FGF21 production promoting agent containing, as an active ingredient, a compound represented by the following formula (1): wherein each of R1 and R2, which may be identical to or different from each other, represents, for example, a hydrogen atom; each of R3a, R3b, R4a, and R4b, which may be identical to or different from one another, represents, for example, a hydrogen atom or a halogen atom, or R3a and R3b or R4a and R4b may bond together to form an alkylenedioxy group; X represents an oxygen atom, a sulfur atom, or N—R5 (R5 represents, for example, a hydrogen atom or a C1-4 alkyl group); Y represents, for example, an oxygen atom, an S(O)l group (l is a number of from 0 to 2), or a carbonyl group; Z represents CH or N; n is a number of from 1 to 6; and m is a number from 2 to 6, a salt of the compound, or a solvate of the compound or the salt.
    Type: Application
    Filed: October 2, 2019
    Publication date: January 30, 2020
    Applicant: Kowa Co., Ltd.
    Inventors: Toshiaki TAKIZAWA, Kentaro MURAKAMI
  • Publication number: 20190167645
    Abstract: The present invention addresses the problem of providing a pharmaceutical combination composition and drug combinations for the prevention and/or treatment of dyslipidemic conditions such as atherosclerosis, hypercholesterolemia, low HDL blood disease in mammals including humans. A pharmaceutical composition for the prevention and/or treatment of dyslipidemia, etc. which comprises (a) a compound represented by the general formula (1) (in the formula, each symbol is the same as defined in the specification) or a salt thereof or a solvate thereof and (b) a cholesterol absorption inhibitor.
    Type: Application
    Filed: February 11, 2019
    Publication date: June 6, 2019
    Applicant: KOWA COMPANY, LTD.
    Inventors: Toshiaki Takizawa, Yasunobu Yoshinaka
  • Publication number: 20190167644
    Abstract: An FGF21 production promoting agent containing, as an active ingredient, a compound represented by the following formula (1): wherein each of R1 and R2 which may be identical to or different from each other, represents, for example, a hydrogen atom; each of R3a, R3b, R4a, and R4b, which may be identical to or different from one another, represents, for example, a hydrogen atom or a halogen atom, or R3a and R3b or R4a and R4b may bond together to form an alkylenedioxy group; X represents an oxygen atom, a sulfur atom, or N—R5 (R5 represents, for example, a hydrogen atom or a C1-4 alkyl group); Y represents, for example, an oxygen atom, an S(O)1 group (l is a number of from 0 to 2), or a carbonyl group; Z represents CH or N; n is a number of from 1 to 6; and m is a number from 2 to 6, a salt of the compound, or a solvate of the compound or the salt.
    Type: Application
    Filed: February 7, 2019
    Publication date: June 6, 2019
    Applicant: Kowa Co. Ltd.
    Inventors: Toshiaki TAKIZAWA, Kentaro MURAKAMI
  • Patent number: 10258609
    Abstract: The present invention addresses the problem of providing a pharmaceutical combination composition and drug combinations for the prevention and/or treatment of dyslipidemic conditions such as atherosclerosis, hypercholesterolemia, low HDL blood disease in mammals including humans. A pharmaceutical composition for the prevention and/or treatment of dyslipidemia, etc. which comprises (a) a compound represented by the general formula (1) (in the formula, each symbol is the same as defined in the specification) or a salt thereof or a solvate thereof and (b) a cholesterol absorption inhibitor.
    Type: Grant
    Filed: February 26, 2018
    Date of Patent: April 16, 2019
    Assignee: KOWA COMPANY, LTD.
    Inventors: Toshiaki Takizawa, Yasunobu Yoshinaka
  • Publication number: 20190030005
    Abstract: This invention provides a combination-drug composition and a combination use of pharmaceuticals for preventing and/or treating dyslipidemia states, such as hyper-LDL cholesterolemia, in mammals, including humans. This invention pertains to a drug composition for preventing and/or treating dyslipidemia and the like, said drug composition comprising the following: (R)-2-[3-[[N-(benzoxazole-2-yl)-N-3-(4-methoxyphenoxy)propyl] aminomethyl]phenoxy] butyric acid, a salt thereof, or a solvate of either; and an omega-3 fatty acid or an ester derivative of an ?-3 fatty acid.
    Type: Application
    Filed: October 3, 2018
    Publication date: January 31, 2019
    Applicant: KOWA COMPANY, LTD.
    Inventor: Toshiaki Takizawa
  • Publication number: 20180185337
    Abstract: The present invention addresses the problem of providing a pharmaceutical combination composition and drug combinations for the prevention and/or treatment of dyslipidemic conditions such as atherosclerosis, hypercholesterolemia, low HDL blood disease in mammals including humans. A pharmaceutical composition for the prevention and/or treatment of dyslipidemia, etc. which comprises (a) a compound represented by the general formula (1) (in the formula, each symbol is the same as defined in the specification) or a salt thereof or a solvate thereof and (b) a cholesterol absorption inhibitor.
    Type: Application
    Filed: February 26, 2018
    Publication date: July 5, 2018
    Applicant: KOWA COMPANY, LTD.
    Inventors: Toshiaki Takizawa, Yasunobu Yoshinaka
  • Patent number: 9968592
    Abstract: This invention provides a combination-drug composition and a combination use of pharmaceuticals for preventing and/or treating dyslipidemic conditions such as hyper-LDL cholesterolemia in mammals, including humans. This invention pertains to a drug composition for preventing and/or treating dyslipidemia and the like, the drug composition including the following: (R)-2-[3-[[N-(benzoxazol-2-yl)-N-3-(4-methoxyphenoxy)propyl]aminomethyl]phenoxy] butyric acid, a salt thereof, or a solvate of either; and (S)-trans-{4-[({2-[({1-[3,5-bis(trifluoromethyl)phenyl]ethyl}{5-[2-(methyl sulfonyl)ethoxy]pyrimidin-2-yl}amino)methyl]-4-(trifluoromethyl)phenyl}(ethyl)amino)methyl]cyclohexyl} acetic acid, a salt thereof, or a solvate of either.
    Type: Grant
    Filed: September 28, 2015
    Date of Patent: May 15, 2018
    Assignee: KOWA COMPANY, LTD.
    Inventors: Yuta Inokuchi, Haruki Shibata, Toshiaki Takizawa
  • Patent number: 9931321
    Abstract: The present invention addresses the problem of providing a pharmaceutical combination composition and drug combinations for the prevention and/or treatment of dyslipidemic conditions such as atherosclerosis, hypercholesterolemia, low HDL blood disease in mammals including humans. A pharmaceutical composition for the prevention and/or treatment of dyslipidemia, etc. which comprises (a) a compound represented by the general formula (1) (in the formula, each symbol is the same as defined in the specification) or a salt thereof or a solvate thereof and (b) a cholesterol absorption inhibitor (1).
    Type: Grant
    Filed: January 6, 2017
    Date of Patent: April 3, 2018
    Assignee: KOWA COMPANY, LTD.
    Inventors: Toshiaki Takizawa, Yasunobu Yoshinaka
  • Publication number: 20180078530
    Abstract: An FGF21 production promoting agent containing, as an active ingredient, a compound represented by the following formula (1): wherein each of R1 and R2, which may be identical to or different from each other, represents, for example, a hydrogen atom; each of R3a, R3b, R4a, and R4b, which may be identical to or different from one another, represents, for example, a hydrogen atom or a halogen atom, or R3a and R3b or R4a and R4b may bond together to form an alkylenedioxy group; X represents an oxygen atom, a sulfur atom, or N—R5 (R5 represents, for example, a hydrogen atom or a C1-4 alkyl group); Y represents, for example, an oxygen atom, an S(O)l group (l is a number of from 0 to 2), or a carbonyl group; Z represents CH or N; n is a number of from 1 to 6; and m is a number from 2 to 6, a salt of the compound, or a solvate of the compound or the salt.
    Type: Application
    Filed: October 18, 2017
    Publication date: March 22, 2018
    Applicant: Kowa Co., Ltd.
    Inventors: Toshiaki TAKIZAWA, Kentaro MURAKAMI
  • Patent number: 9888746
    Abstract: This surface fastener has a substrate portion and a plurality of engaging elements, each of the engaging elements being provided with a stem portion standing from the substrate portion and a hook portion extending in the fastener width direction from the stem portion. The engaging element has a narrow width tip end portion provided with at least a hook portion and an enlarged width portion provided with only the stem portion, separated by a reference surface along the fastener length and height directions as a boundary. This makes an undercut hardly formable in the molding of the engaging element, and deficiencies such as deformation and the like of the engaging element can be prevented. Further, the strength of the stem portion can be increased, and a damage which a loop-shaped engaging element and the engaging element receive when the loop-shaped engaging element is attached or pulled out can be reduced.
    Type: Grant
    Filed: March 13, 2015
    Date of Patent: February 13, 2018
    Assignee: YKK Corporation
    Inventors: Ryuichi Murasaki, Tomonari Yoshida, Yoshitomo Iyoda, Toshiaki Takizawa
  • Publication number: 20170304274
    Abstract: This invention provides a combination-drug composition and a combination use of pharmaceuticals for preventing and/or treating dyslipidemic conditions such as hyper-LDL cholesterolemia in mammals, including humans. This invention pertains to a drug composition for preventing and or treating dyslipidemia and the like, the drug composition including the following: (R)-2-[3-[[N-(benzoxazol-2-yl)-N-3-(4-methoxyphenoxy)propyl]aminomethyl]phenoxy] butyric acid, a salt thereof, or a solvate of either; and nicotinic acid and nicotinic-acid amide, collectively referred to as niacin, an ester derivative thereof, a salt thereof, or a solvate of any of these.
    Type: Application
    Filed: September 28, 2015
    Publication date: October 26, 2017
    Applicant: KOWA COMPANY, LTD.
    Inventors: Yuta Inokuchi, Toshiaki Takizawa
  • Publication number: 20170304273
    Abstract: This invention provides a combination-drug composition and a combination use of pharmaceuticals for preventing and/or treating dyslipidemic conditions such as hyper-LDL cholesterolemia in mammals, including humans. This invention pertains to a drug composition for preventing and/or treating dyslipidemia and the like, the drug composition including the following: (R)-2-[3-[[N-(benzoxazol-2-yl)-N-3-(4-methoxyphenoxy)propyl]aminomethyl]phenoxy] butyric acid, a salt thereof, or a solvate of either; and (S)-trans-{4-[({2-[({1-[3,5-bis(trifluoromethyl)phenyl]ethyl}{5-[2-(methylsulfonyl)ethoxy]pyrimidin-2-yl}amino)methyl]-4-(trifluoromethyl)phenyl}(ethyl)amino)methyl]cyclohexyl} acetic acid, a salt thereof, or a solvate of either.
    Type: Application
    Filed: September 28, 2015
    Publication date: October 26, 2017
    Applicant: KOWA COMPANY, LTD.
    Inventors: Yuta Inokuchi, Haruki Shibata, Toshiaki Takizawa